Latest News

Category: Clinical

See all

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

ASX, Clinical, News,

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.   ASCO GU, the leading specialised event for GU cancer care worldwide, will be...

Read more

First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy

ASX, Clinical, News,

Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent...

Read more

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...

Read more

Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022

Clinical, News,

Telix is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today...

Read more

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

Clinical, News,

Telix today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The...

Read more

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...

Read more

First Patient Enrolled in ProstACT TARGET Study

ASX, Clinical, News,

Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s...

Read more

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

ASX, Clinical, News,

Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent...

Read more

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

ASX, Clinical, News,

Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)...

Read more